FCX Stock Chart Sat, Feb 1st, 2014

New Post Public Reply Private Reply Replies (0) Message Board
chartguy89
FCX Stock Chart and Technical Analysis - Sat, Feb 1st, 2014 $FCX

Period  Moving Average  Price Change  Percent Change  Average Volume
5 Day  32.42  -0.36  -1.10%  11,799,800
20 Day  34.94  -5.22  -13.87%  13,131,160
50 Day  35.27  -4.08  -11.18%  10,515,998
100 Day  35.08  +0.57  +1.79%  11,397,903
200 Day  32.52  +4.41  +15.75%  13,842,436
Year to Date  35.07  -5.33  -14.12%  12,936,705

Period  Raw Stochastic  Stochastic %K  Stochastic %D  Average True Range
9 Day 11.71% 9.12% 8.92% 0.78
14 Day 9.01% 8.22% 8.62% 0.77
20 Day 8.22% 7.25% 7.50% 0.75
50 Day 7.79% 7.11% 7.45% 0.74
100 Day 10.69% 14.96% 18.89% 0.78

Period  Relative Strength  Percent R  Historic Volatility  MACD Oscillator
9 Day 23.01% 88.29% 16.63% -0.76
14 Day 28.49% 90.99% 22.25% -1.88
20 Day 33.13% 91.78% 20.24% -2.56
50 Day 44.13% 92.21% 18.38% -2.88
100 Day 48.08% 89.31% 20.33% -2.69

FCX Stock Chart and Technical Analysis - Sat, Feb 1st, 2014
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Celltrion Unveils New Data on Infliximab: ACG 2026 Insight

Updated Category News Views 34

First Impressions: Celltrion's Latest Revelation Alright, let's jump straight into it. Celltrion USA is flaunting its latest findings on ZYMFENTRA® (infliximab-dyyb) for Crohn's disease and ulcerative colitis right at the American College of Gastroenterology's (ACG) grand event in 2026. If you've been watching the healthcare sector, this is significant news. It's got all...

Continue Reading
AbbVie's SKYRIZI and RINVOQ Highlight IBD Control Advances

Updated Category News Views 35

A Deeper Look Into AbbVie's Latest Data Let's cut straight to the science, folks. At the recent American College of Gastroenterology 2026 Annual Scientific Meeting, AbbVie pulled the curtain on 22 fresh scientific abstracts that are really shaking things up in the field of inflammatory bowel disease (IBD) treatment. Data from the Phase 3 AFFIRM study shined especially...

Continue Reading
Sebela Pharma's Tegoprazan Posts Strong Phase 3 Data

Updated Category News Views 24

Spotlight on Tegoprazan: A New Player on the GERD Field Sometimes, a pharma company turns heads with data that speaks for itself. This time, Sebela Pharmaceuticals is doing just that with Tegoprazan's phase 3 results, shining a light on an area overlooked for too long: non-erosive reflux disease (NERD). Showing promise in its latest trials, Tegoprazan is muscling into the...

Continue Reading
2026 Community Impact Week: Slam Dunk for Community Unity

Updated Category News Views 26

Alright, if you're looking for a story that gives you those warm fuzzy feelings while wrapping you in a big sports hug, here it is. Imagine this: you've got basketball legends, world-class athletes, and a corporate heavyweight, all huddling up to make a community impact that's more than just warm air. Hoops, Hope, and High Fives The NBA Cares x Sands Cares Community...

Continue Reading
Duolingo Faces Lawsuit Over Alleged Investor Missteps

Updated Category News Views 37

Fasten your seatbelts, folks. We're diving into a legal tussle that could shake things up for Duolingo, Inc. (NASDAQ: DUOL). Investors who plunged into Duolingo shares between May 2, 2025, and February 26, 2026, might be feeling the heat now. They ought to brace for a class-action lawsuit frenzy with fingers pointed at Duolingo for allegedly pulling wool over investors'...

Continue Reading
LEGO Mashes Star Wars and Marvel for Fans' Delight

Updated Category News Views 35

A New Chapter in LEGO's Story Well, well, what do we have here? LEGO's throwing down the gauntlet. For the first time, they're asking fans to merge two colossal universes: Star Wars and Marvel. Talk about a brains-and-bricks bonanza! Announced at New York Comic Con with some star power from Kevin Smith, this LEGO Ideas challenge opens doors for fan creativity that might...

Continue Reading
Pacira BioSciences Faces Shareholder Revolt in M&A Deal

Updated Category News Views 4

A New Storm Brews Over Pacira's Sale to Viatris They say where there's smoke, there's fire, and it looks like Pacira BioSciences, Inc. (NASDAQ: PCRX) is running right into a bonfire thanks to their upcoming sale to Viatris Inc. On the face of it, shareholders are looking at a tidy $36.50 in cash per share, but not everyone's buying the deal as fair. Enter lawman Juan...

Continue Reading

Top 5 Most Recently Viewed Articles

Man Group PLC Highlights Its Strategic Disclosures on Tritax REIT

Updated Category News Views 148

Strategic Position Disclosure by Man Group PLC Man Group PLC is actively sharing its significant interests in the securities market, particularly focusing on its involvement with Tritax Big Box REIT plc. As a key player in the investment landscape, this disclosure marks an important step for the company regarding its strategic holdings. Key Information Pertaining to the...

Continue Reading
TalentLMS and Epignosis Lead the Way in GDPR Compliance

Updated Category News Views 720

TalentLMS and Epignosis Set the Standard for GDPR Compliance TalentLMS, along with its parent company Epignosis, has continuously led the way in providing a fully compliant Learning Management System (LMS) with regards to the General Data Protection Regulation (GDPR). Recent developments affirm that TalentLMS remains the only LMS globally to uphold its commitment to this...

Continue Reading
Zillow and Esusu Forge New Path to Boost Renters' Credit Scores

Updated Category News Views 283

Building Credit for Renters with Zillow and Esusu The recent collaboration between Zillow and Esusu marks a significant step towards empowering renters across the country to build their credit. This partnership allows any renter to report their on-time rent payments, significantly enhancing their credit profiles, for just $20 a year. How the Partnership Works Starting...

Continue Reading
iCrowdNewswire Leverages DeepL for Enhanced Global Communication

Updated Category News Views 121

iCrowdNewswire Enhances Multilingual Capabilities iCrowdNewswire, a prominent international press release distribution company, has embarked on a transformative journey to improve its multilingual services through the introduction of the DeepL API. The integration of DeepL's cutting-edge language AI technology has significantly boosted iCrowdNewswire’s ability to...

Continue Reading
Celebrating Excellence: Top Surgeons Recognized in Endocrine Care

Updated Category News Views 82

Exceptional Recognition for Leading Surgeons in Endocrine Surgery Dr. Jim Norman and Dr. Gary Clayman Acknowledged as Premier Specialists The Hospital for Endocrine Surgery is proud to announce that two of its distinguished surgeons, Dr. Jim Norman and Dr. Gary Clayman, have been honored in the prestigious Castle Connolly Top Doctors list for 2025. This remarkable...

Continue Reading